Defunct Company
Total Trials
5
As Lead Sponsor
2
As Collaborator
3
Total Enrollment
1,020
NCT00088166
XERECEPT® (hCRF) for Patients Requiring Dexamethasone to Treat Edema Associated With Brain Tumors
Phase: Phase 3
Role: Collaborator
Start: May 31, 2004
Completion: Mar 31, 2008
NCT00226655
An Open-Labeled, Extended-Use of XERECEPT (hCRF) for Patients in Studies NTI 0302, 0303, or Other Designated Studies
Start: Jul 31, 2005
Completion: Apr 30, 2009
NCT00141011
Ancrod (Viprinex™) for the Treatment of Acute, Ischemic Stroke
Role: Lead Sponsor
Start: Sep 30, 2005
Completion: Dec 31, 2008
NCT00226668
XERECEPT® (hCRF) for Primary Glioma Patients Requiring Dexamethasone to Treat Peritumoral Brain Edema
Start: Jan 31, 2006
Completion: Jan 31, 2008
NCT00300196
ASP-II: Ancrod Stroke Program: Ancrod (Viprinex™) for the Treatment of Acute, Ischemic Stroke
Start: Mar 31, 2006